OpSens Announces Completion of Enrollment in SAFE-TAVI Study With SavvyWire in Europe

Quebec City, Quebec, April 11, 2023 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced the successful completion of enrollment in the SAFE‑TAVI clinical study, studying left ventricular rapid pacing using SavvyWire in transcatheter aortic valve implantation procedures (TAVI or TAVR), in Europe.  The study enrolled 120 patients with severe aortic valve stenosis and other conditions requiring a TAVI procedure in which left ventricular rapid pacing was considered necessary.

The SAFE-TAVI study was conducted in nine hospitals including eight renowned centers across Spain and one in Canada, at Quebec Heart and Lung Institute – Laval University (IUCPQ).  As the global principal investigator of the SAFE-TAVI study, Dr. Josep Rodés-Cabau from IUCPQ oversaw and coordinated the principal investigators in their respective Spanish hospitals. OpSens’ SavvyWire was used for left ventricular pacing to evaluate the potential benefits of eliminating the need for venous access, reducing procedure time, and avoiding potential complications associated with right ventricular pacing.

“We successfully used the SavvyWire in a large variety of anatomies, implanting valves from all major companies, including Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific,” said Dr. Rodés-Cabau. “Left ventricular rapid pacing is necessary to restrict the range of motion of the heart muscle during TAVI for optimal valve placement. The rapid pacing feature is important in SavvyWire’s performance in addition to providing real-time, accurate hemodynamic measurement during the TAVI procedure.”

“We are honored to partner with Dr. Rodés-Cabau and all investigators on SAFE-TAVI,” said Louis Laflamme, President and CEO of OpSens. “His clinical work has been instrumental in the progression of the TAVI procedure and the treatment of aortic stenosis and many advances in cardiology. We anticipate the clinical data from the SAFE-TAVI study will be published later this year.”

OpSens’ received Health Canada and U.S. FDA clearance for SavvyWire in 2022.  The SAFE-TAVI clinical study is being conducted as part of OpSens CE Mark clinical strategy for the commercialization of SavvyWire in Europe.

SavvyWire is more than a wire.  It is the world’s first and only sensor-guided TAVR solution.  SavvyWire uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.

Learn more about the SAFE-TAVI study here: https://clinicaltrials.gov/ct2/show/NCT05492383

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    OpSens Medical. (2023, April 19). OpSens Announces Completion of Enrollment in SAFE-TAVI Study With SavvyWire in Europe. AZoSensors. Retrieved on May 30, 2024 from https://www.azosensors.com/news.aspx?newsID=15440.

  • MLA

    OpSens Medical. "OpSens Announces Completion of Enrollment in SAFE-TAVI Study With SavvyWire in Europe". AZoSensors. 30 May 2024. <https://www.azosensors.com/news.aspx?newsID=15440>.

  • Chicago

    OpSens Medical. "OpSens Announces Completion of Enrollment in SAFE-TAVI Study With SavvyWire in Europe". AZoSensors. https://www.azosensors.com/news.aspx?newsID=15440. (accessed May 30, 2024).

  • Harvard

    OpSens Medical. 2023. OpSens Announces Completion of Enrollment in SAFE-TAVI Study With SavvyWire in Europe. AZoSensors, viewed 30 May 2024, https://www.azosensors.com/news.aspx?newsID=15440.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.